Vertex Pharmaceuticals (VRTX) vs peers
VRTX's EV/EBITDA is 25.2x, compared with 19.1x at the middle of 4 peers.
Biotechnology. Updated .
| Stock | EV/EBITDA | Own 5-year rank |
|---|---|---|
| VRTXVertex Pharmaceuticals | 25.2x | 84% |
| ABBVAbbVie | 22.6x | 88% |
| AMGNAmgen | 19.9x | 91% |
| REGNRegeneron Pharmaceuticals | 18.2x | 71% |
| INCYIncyte | 11.7x | 14% |
| GILDGilead Sciences | Unavailable | Unranked |
| MRNAModerna | Unavailable | Unranked |
How to read this comparison
Up to eight covered companies in the same industry, largest market value first.
EV/EBITDA divides enterprise value (stock market value plus debt, less cash) by earnings before interest, tax, depreciation and amortization from the previous twelve months. The middle peer reading excludes VRTX and unavailable values.
Own 5-year rank compares each stock with its available weekly readings within the last five years. At least 26 usable weeks are required. A rank of 20% means its current multiple is above 20% of its past readings. It is not a rank against the other stocks in this table.
Dates show data updates; the latest available weekly observation can differ between stocks. Different growth rates, margins and financial risks can explain different multiples. Missing or non-positive denominators are left unranked.